Spring 2025 | XL Edition
PEDIATRIC SURVIVOR SERIES
The Forbeck Foundation is excited to partner with Curing Kids Cancer (CKC), which is celebrating its 20th anniversary and has raised over $30 million to fund pediatric cancer research and treatment. After being introduced to the Foundation, Gráinne Owen, founder of CKC, attended the February 2024 Forbeck Forum to observe how our meetings operate. Inspired by what she saw, she was eager to collaborate on a Forum series focused on addressing the key challenges facing pediatric cancer survivors. The good news is that more children are surviving cancer than ever before. However, survivors face lifelong challenges due to the toxic effects of treatment, including secondary malignancies, financial burdens, and psychological tolls. There is a significant need for focused research and support to improve long-term outcomes.
In collaboration with Gráinne and CKC, we’ve identified the first two Forums in the series that will take place October 26-29, 2025 in Lake Geneva, WI.
SUBSEQUENT CANCER RISK IN PEDIATRIC CANCER SURVIVORS Chaired by Dr. Greg Armstrong (St. Jude) and Dr. Lindsay Morton (NIH) .
While advancements in pediatric cancer treatment have led to higher survival rates, subsequent cancers remain a significant concern. These secondary cancers are among the leading causes of morbidity and mortality in childhood cancer survivors. This Forum will bring together an interdisciplinary group of leading experts to drive the design and execution of clinical and population studies aimed at reducing subsequent cancer risk and improving outcomes for pediatric cancer survivors. The session will explore the impact of radiotherapy, systemic therapy, genetics, and lifestyle factors in mitigating the risk of subsequent cancers. TECHNOLOGY TO ADVANCE CARE AND OUTCOMES FOR PEDIATRIC CANCER SURVIVORS Chaired by Dr. Melissa Hudson (St. Jude Children’s Research Hospital), Dr. Lisa Diller (Dana-Farber), and Dr. Tara Henderson (University of Chicago) . Adolescents and young adults with cancer (AYAs, ages 15–39) face unique challenges—balancing treatment with education, work, and social relationships—while often lacking the support and resources available to younger children and older adults. As part of the White House Cancer Moonshot’s CC-DIRECT initiative, CC-Connect has worked to identify key strategies to better support AYAs and their families. These strategies form a comprehensive framework aimed at improving outcomes and enhancing the cancer care experience for this vulnerable group. By bringing together top experts, this Forum will explore how technology and innovation can bridge gaps in care, ensuring that more young survivors receive the support, guidance, and treatment they need to thrive.
2025 FORUMS - Sex Differences in Etiology, Epidemiology, and Treatment of Cancer - Harnessing stroma-immune interactions for anti-cancer therapy - Mitochondrial Stress in Cancer - RNA Modifications in mRNA Translation and Cancer - Targeting Mitochondria in Cancer (immuno)therapy - Targeting Cancer Evolution - Persistence, Apoptosis, and Minimal Residual Disease - Nucleosome Structure and Function in Cancer - Cell Death in Cancer Therapy - AI in Cancer - Subsequent Cancer Risk After Pediatric Cancer - Technology to Advance Care and Outcomes for Pediatric Cancer Survivors - Targeting Immunometabolism for Cancer Therapy
FORBECKFORUMS.ORG
3
Made with FlippingBook - professional solution for displaying marketing and sales documents online